Quick Answer
LIGAND PHARMACEUTICALS INC reported Operating Income Loss of $41.00 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +281.4% in Operating Income Loss from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: -$3.40 million | Q1 2012: -$839.0 thousand | Q2 2012: -$1.82 million | Q3 2012: -$1.43 million | Q1 2013: $3.93 million | Q2 2013: $1.51 million | Q3 2013: $3.07 million | Q1 2014: $5.10 million | Q2 2014: $1.36 million | Q3 2014: $3.53 million | Q1 2015: $3.35 million | Q2 2015: $4.37 million | Q3 2015: $8.60 million | Q1 2016: $15.10 million | Q2 2016: $3.97 million | Q3 2016: $5.47 million | Q1 2017: $10.22 million | Q2 2017: $13.02 million | Q3 2017: $16.49 million | Q1 2018: $37.04 million | Q2 2018: $70.18 million | Q3 2018: $23.36 million | Q1 2019: $826.54 million | Q2 2019: -$4.13 million | Q3 2019: -$5.16 million | Q1 2020: $3.79 million | Q2 2020: $7.10 million | Q3 2020: $3.75 million | Q1 2021: $4.72 million | Q2 2021: $45.74 million | Q3 2021: $15.71 million | Q1 2022: $2.13 million | Q2 2022: $8.66 million | Q3 2022: $12.34 million | Q1 2023: $14.21 million | Q2 2023: -$1.98 million | Q3 2023: $3.08 million | Q1 2024: $2.99 million | Q2 2024: -$19.10 million | Q3 2024: $3.14 million | Q1 2025: -$36.22 million | Q2 2025: $8.44 million | Q3 2025: $54.93 million.
- Over the full 17 years of available data (2009 to 2025), LIGAND PHARMACEUTICALS INC's Operating Income Loss has grown by 511.4%.
- Historical annual values: Fiscal year 2025: $41.00 million | Fiscal year 2024: -$22.61 million | Fiscal year 2023: $11.94 million | Fiscal year 2022: $3.04 million | Fiscal year 2021: $103.85 million | Fiscal year 2020: $37.50 million | Fiscal year 2019: $807.08 million | Fiscal year 2018: $163.73 million | Fiscal year 2017: $68.08 million | Fiscal year 2016: $43.89 million | Fiscal year 2015: $27.33 million | Fiscal year 2014: $19.63 million | Fiscal year 2013: $14.94 million | Fiscal year 2012: $193.0 thousand | Fiscal year 2011: -$878.0 thousand | Fiscal year 2010: -$29.30 million | Fiscal year 2009: -$9.97 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: